short acting glp 1 agonists Short‐acting glucagon‐like peptide‐1 receptor as add‐on to insulin therapy in type diabetes: A review - Albèr - 2017 - Diabetes, Obesity and Metabolism Effects of GLP-1 and Its

Acetaldehyde and malondialdehyde react together to generate distinct protein adducts in the liver during long-term ethanol administration

Often called the "master antioxidant," it helps neutralise free radicals, support liver health, and maintain healthy skin and brain function

According to statistics, there are currently approximately 50 million people living with AD worldwide, and this number is expected to increase to 152 million by 2050 as the population ages, making it a major challenge for global public health ( The glucagon-like peptide-1 receptor (GLP-1R) is a key target for diabetes mellitus (DM) treatment, and GLP-1R agonists are pharmaceutical compounds employed in the treatment of DM

& Anderson, M